J4T0 Stock Overview
A biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Onconetix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.82 |
| 52 Week High | US$19.37 |
| 52 Week Low | US$2.74 |
| Beta | 3.66 |
| 11 Month Change | -38.70% |
| 3 Month Change | -47.78% |
| 1 Year Change | -85.25% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| J4T0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 4.5% |
| 1Y | -85.3% | -16.4% | 13.5% |
Return vs Industry: J4T0 underperformed the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: J4T0 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| J4T0 volatility | |
|---|---|
| J4T0 Average Weekly Movement | 25.2% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: J4T0's share price has been volatile over the past 3 months.
Volatility Over Time: J4T0's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Ralph Schiess | onconetix.gcs-web.com |
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. Fundamentals Summary
| J4T0 fundamental statistics | |
|---|---|
| Market cap | €3.97m |
| Earnings (TTM) | -€47.47m |
| Revenue (TTM) | €1.31m |
3.0x
P/S Ratio-0.1x
P/E RatioIs J4T0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J4T0 income statement (TTM) | |
|---|---|
| Revenue | US$1.46m |
| Cost of Revenue | US$2.30m |
| Gross Profit | -US$837.45k |
| Other Expenses | US$52.29m |
| Earnings | -US$53.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -71.33 |
| Gross Margin | -57.21% |
| Net Profit Margin | -3,629.25% |
| Debt/Equity Ratio | -52.6% |
How did J4T0 perform over the long term?
See historical performance and comparison